Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Pan, H., Peto, R., Karim, Q. A., Alejandria, M. M., Henao-Restrepo, A. M., Garcia, P. J., Kiény, M.-P., Malekzadeh, R., Murthy, S., Préziosi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,748 · see citing works

Identification of a new human coronavirus

van der Hoek, L., Pyrć, K., Jebbink, M. F., Vermeulen-Oost, W., Berkhout, R. J. M., Wolthers, K. C., Dillen, P. M. E. W., Kaandorp, J. C., Spaargaren, J., & Berkhout, B. (2004) · Nature Medicine · doi:10.1038/nm1024 · Cited by 1,868 · see citing works

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Sheahan, T. P., Sims, A. M., Zhou, S., Graham, R. L., Pruijssers, A. J. P., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,069 · see citing works

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Ianevski, A., Giri, A. K., & Aittokallio, T. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa216 · Cited by 882 · see citing works

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., & Pöhlmann, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409465102 · Cited by 824 · see citing works

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18233-x · Cited by 544 · see citing works

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R. S., Mollan, K. R., Wolfe, C. R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7430 · Cited by 531 · see citing works

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Wahl, A. R., Gralinski, L. E., Johnson, C. E., Yao, W., Kovářová, M., Dinnon, K. H., Liu, H., Madden, V. J., Krzystek, H. M., De, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03312-w · Cited by 402 · see citing works

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Cox, R. M., Wolf, J. D., & Plemper, R. K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00835-2 · Cited by 391 · see citing works

Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Agostini, M. L., Pruijssers, A. J. P., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R., Lockwood, M. A., Sheahan, T. P., Sims, A. M., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01348-19 · Cited by 328 · see citing works

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Toots, M., Yoon, J.-J., Cox, R. M., Hart, M., Sticher, Z. M., Makhsous, N., Plesker, R., Barrena, A. H., Reddy, P. G., Mitchell, D. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5866 · Cited by 327 · see citing works

Molnupiravir, an Oral Antiviral Treatment for COVID-19Preprint

Fischer, W. A., Eron, J. J., Holman, W., et al. (2021) · medRxiv · doi:10.1101/2021.06.17.21258639 · Cited by 221 · see citing works

Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture

Stuyver, L. J., Whitaker, T., McBrayer, T. R., Hernández-Santiago, B. I., Lostia, S., Tharnish, P. M., Ramesh, M., Chu, C. K., Jordan, R., Shi, J., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.244-254.2003 · Cited by 200 · see citing works

β- d - N 4 -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome

Urakova, N., Kuznetsova, V., Crossman, D. K., Sokratian, A., Guthrie, D. B., Kolykhalov, A. A., Lockwood, M. A., Natchus, M. G., Crowley, M. R., Painter, G. R., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01965-17 · Cited by 194 · see citing works

A time-of–drug addition approach to target identification of antiviral compounds

Daelemans, D., Pauwels, R., Clercq, E. D., & Pannecouque, C. C. (2011) · Nature Protocols · doi:10.1038/nprot.2011.330 · Cited by 148 · see citing works

Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication

Reynard, O., Nguyen, X.-N., Alazard-Dany, N., Barateau, V., Cimarelli, A., & Volchkov, V. E. (2015) · Viruses · doi:10.3390/v7122934 · Cited by 112 · see citing works

More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults

da Veiga, A. B. G., Martins, L. G., Riediger, I. N., Mazetto, A., Debur, M. D. C., & Gregianini, T. S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26362 · Cited by 58 · see citing works

Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses

Ma, Z., Li, P., Ji, Y., Ikram, A., & Pan, Q. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30098-7 · Cited by 50 · see citing works

Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context

Li, P., Liu, J., Ma, Z., Bramer, W. M., Peppelenbosch, M. P., & Pan, Q. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa321 · Cited by 18 · see citing works

Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses

Li, P., Ikram, A., Peppelenbosch, M. P., Ma, Z., & Pan, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1386 · Cited by 15 · see citing works

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis

Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298 · see citing works

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Li, P., Wang, Y., Lavrijsen, M., Lamers, M. M., de Vries, A. C., Rottier, R. J., Bruno, M. J., Peppelenbosch, M. P., Haagmans, B. L., & Pan, Q. (2022) · Cell Research · doi:10.1038/s41422-022-00618-w · Cited by 205 · see citing works

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study

Marzi, M., Vakil, M. K., Bahmanyar, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/7341493 · Cited by 137 · see citing works

Antiviral Drug Discovery for the Treatment of COVID-19 Infections

Ng, T. I., Correia, I., Seagal, J., DeGoey, D. A., Schrimpf, M. R., Hardee, D. J., Noey, E. L., & Kati, W. M. (2022) · Viruses · doi:10.3390/v14050961 · Cited by 97 · see citing works

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review

Masyeni, S., Iqhrammullah, M., Frediansyah, A., Nainu, F., Tallei, T. E., Emran, T. B., Ophinni, Y., Dhama, K., & Harapan, H. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27730 · Cited by 75 · see citing works

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice

Jeong, J. H., Chokkakula, S., Min, S. C., Kim, B. K., Choi, W.-S., Oh, S., Yun, Y. S., Kang, D. H., Lee, O.-J., Kim, E., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105430 · Cited by 74 · see citing works

Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)

Ramu, R. (2021) · Bioinformation · doi:10.6026/97320630017932 · Cited by 65 · see citing works

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19

Atmar, R. L., & Finch, N. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02404-21 · Cited by 51 · see citing works

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Teli, D., Balar, P. C., Patel, K. P., Sharma, A., Chavda, V. P., & Vora, L. K. (2023) · Metabolites · doi:10.3390/metabo13020309 · Cited by 45 · see citing works

A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable

Cookson, W., Moffatt, M. F., Rapeport, G., & Quint, J. K. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2389ci · Cited by 40 · see citing works

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

Stegmann, K. M., Dickmanns, A., Heinen, N., Blaurock, C., Karrasch, T., Breithaupt, A., Klopfleisch, R., Uhlig, N., Eberlein, V., Issmail, L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104293 · Cited by 44 · see citing works

Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method

Annadi, A. M., Zahar, N. M. E., El‐Sattar, N. E. A. A., Mohamed, E. H., Mahmoud, S. A., & Attia, M. S. (2022) · RSC Advances · doi:10.1039/d2ra05066h · Cited by 39 · see citing works

Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses

Li, J., Wang, Y., Solanki, K., Atre, R., Lavrijsen, M., Pan, Q., Baig, M. S., & Li, P. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105555 · Cited by 31 · see citing works

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system

Punekar, M., Kshirsagar, M. M., Tellapragada, C., & Patil, K. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105608 · Cited by 29 · see citing works

SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19

Afshar, Z. M., Pirzaman, A. T., Karim, B., Anaraki, S. R., Hosseinzadeh, R., Pireivatlou, E. S., Babazadeh, A., Hosseinzadeh, D., Miri, S. R., Sio, T. T. W., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13030559 · Cited by 29 · see citing works

Preparation and Characterization of Fe-Gallic acid MOF for determination of antiviral Molnupiravir as inhibitor for RNA Corona virus replication

Younis, H. M., Youssef, A. O., El‐Sheikh, S. M., Sheta, S. M., & Attia, M. S. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109297 · Cited by 28 · see citing works

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo

Li, Y., Liu, M., Yan, Y., Wang, Z., Dai, Q., Yang, X., Guo, X., Li, W., Chen, X., Cao, R., et al. (2022) · Viruses · doi:10.3390/v14061142 · Cited by 26 · see citing works

DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response

Huang, Z., Zhang, P., & Deng, L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad244 · Cited by 25 · see citing works

Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids

Li, P., Wang, Y., Lamers, M. M., Lavrijsen, M., Iriondo, C., de Vries, A. C., Rottier, R. J., Peppelenbosch, M. P., Haagmans, B. L., & Pan, Q. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104132 · Cited by 21 · see citing works

Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor

Weil, T., Lawrenz, J., Seidel, A., Münch, J., & Müller, J. A. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105343 · Cited by 21 · see citing works

SARS-CoV-2 Resistance to Small Molecule Inhibitors

Lopez, U. M., Hasan, M. M., Havranek, B., & Islam, S. M. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00229-6 · Cited by 20 · see citing works

A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2

Chaube, U. J., Patel, B., & Bhatt, H. G. (2022) · 3 Biotech · doi:10.1007/s13205-022-03430-w · Cited by 9 · see citing works

De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design

Shehzadi, K., Yu, M., & Liang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417473 · Cited by 11 · see citing works

Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir

Wang, Y., Li, P., Lavrijsen, M., Rottier, R. J., den Hoed, C. M., Bruno, M. J., Kamar, N., Peppelenbosch, M. P., de Vries, A. C., & Pan, Q. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12417 · Cited by 8 · see citing works

Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study

Ibrahim, M. A. A., Shehata, M. N. I., Moussa, N. A. M., Hemia, R. R. A., Elhafez, H. S. M. A., El‐Rahman, M. K. A., Sayed, S. R. M., Sidhom, P. A., Dabbish, E., & Shoeib, T. (2023) · ACS Omega · doi:10.1021/acsomega.3c03215 · Cited by 9 · see citing works

Roles of Sialyl Glycans in HCoV-OC43, HCoV-HKU1, MERS-CoV and SARS-CoV-2 Infections

Sriwilaijaroen, N., & Suzuki, Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2635-1_17 · Cited by 8 · see citing works

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study

Zheng, Q., Bao, C., Ji, Y., Li, P., Ma, Z., Wang, X., Meng, Q., & Pan, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-32619-z · Cited by 8 · see citing works

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery

Li, J., Wang, X., Ding, Y., Qin, F., de Lima, S. T. S., Papamichail, L., Schraauwen, R., Forato, J., Claro, I. M., Hua, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102646 · Cited by 7 · see citing works

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19

Kulkarni, P., & Padmanabhan, S. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03259-6 · Cited by 8 · see citing works

Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable

Li, Y., Wang, Y., Li, Y., de Vries, A. C., Li, P., Peppelenbosch, M. P., & Pan, Q. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105674 · Cited by 6 · see citing works

Purine but Not Pyrimidine De Novo Nucleotide Biosynthesis Inhibitors Strongly Enhance the Antiviral Effect of Corresponding Nucleobases Against Dengue Virus

Bonnac, L. F., Dreis, C. D., Rai, M., & Geraghty, R. J. (2025) · Molecules · doi:10.3390/molecules30020210 · Cited by 5 · see citing works

Conserved Targets to Prevent Emerging Coronaviruses

Lomeli, F. G., Elmaraghy, N., Castro, A., Osuna, C., & Newcomb, L. L. (2022) · Viruses · doi:10.3390/v14030563 · Cited by 4 · see citing works

SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2

Pandey, K., Acharya, A., Pal, D., Jain, P., Singh, K. D., Durden, D. L., Kutateladze, T. G., Deshpande, A. J., & Byrareddy, S. N. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105904 · Cited by 3 · see citing works

From Batch to Continuous Flow Synthesis in Enzymatic Process Towards Molnupiravir

Hongnak, S., Vorasin, O., Aunbamrung, P., Techapanalai, S., Tiyasakulchai, T., Sonwong, W., Jaito, N., Thongpanchang, C., Whungsinsujaritb, S., Srikun, O., et al. (2024) · Chemistry - An Asian Journal · doi:10.1002/asia.202401134 · Cited by 2 · see citing works

The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo

Feng, X., Yang, X., Hu, X., Liu, Q., Ding, Y., Cao, X., Ma, Z., & Ma, X. (2025) · Virology · doi:10.1016/j.virol.2025.110642 · Cited by 2 · see citing works

Repurposing of the nucleoside analogs for influenza

Mee-udorn, P., Narkpuk, J., Jaru-Ampornpan, P., Hongeng, S., Uengwetwanit, T., & Srimongkolpithak, N. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.08.006 · Cited by 2 · see citing works

BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS

Vasilyuk, V. B., Boroduleva, A. Y., Соболев, П. Д., Никифорова, А. Г., Mozgovaya, V. G., Filon, O. V., Zinkovskaya, A. V., Ignatiev, V. G., MIu, S., Kozlova, I. S., et al. (2023) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2022-10-6-562-572 · Cited by 2 · see citing works

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Johnson, M. G., Strizki, J., Jensen, E. H., Cohen, J., Katlama, C., Fishchuk, R., Ponce‐de‐León, A., Fourie, N., Cheng, C., McCoy, D., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03563-23 · Cited by 2 · see citing works

Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

Lorenz, D., & Pawliczak, R. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114394 · Cited by 2 · see citing works

The Relationship Between Illness Perception and Coping Strategies in Cancer Patients Undergoing Chemotherapy

Yılmaz, Y., Gürbüz, M., & Şenler, F. Ç. (2024) · Journal of Ankara University Faculty of Medicine · doi:10.4274/atfm.galenos.2024.68095 · Cited by 1 · see citing works

Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation

Chen, W., Ji, M. C., Jung, E., Shin, J. S., Yeh, J., Chen, Z., Zhou, B., & Go, Y. Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124357 · Cited by 1 · see citing works

Antiviral nucleoside mimics: the development and future perspective of Molnupiravir

Khalil, A. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2684621 · Cited by 1 · see citing works

Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of COVID-19

Handali, S., Haririan, I., Vaziri, M., & Dorkoosh, F. A. (2022) · Drug Delivery Letters · doi:10.2174/2210303112666220829125054 · Cited by 1 · see citing works

A retrospective whole genome sequencing of SARS-CoV-2 isolate from respiratory sample of an individual from Ota – Ogun State, Nigeria

Joseph, O. O., Dahunsi, S. O., & Okoh, A. (2024) · Gene Reports · doi:10.1016/j.genrep.2024.102032

Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells

Doki, T., Shinohara, K., To, K., & Takano, T. (2025) · Pathogens · doi:10.3390/pathogens14080787

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Yip, A. J. W., Low, Z. Y., Chow, V. T. K., & Lal, S. K. (2022) · Viruses · doi:10.3390/v14061345 · Cited by 50 · see citing works

Exploring molnupiravir (EIDD-2801) by molecular docking, temperature-dependent dynamics simulations, and DFT calculations on the RNA-dependent RNA polymerase (RdRp) from SARS-CoV-2

da Silva‐Júnior, E. F., & da Silva, L. R. N. (2021) · International Electronic Conference on Medicinal Chemistry (ECMC) · doi:10.3390/ecmc2021-11433

RdRp inhibitors and COVID-19: Is molnupiravir a good option?

Hashemian, S. M. R., Pourhanifeh, M. H., Hamblin, M. R., Shahrzad, M. K., & Mirzaei, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112517 · Cited by 84 · see citing works

Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations

Carbone, J., Paradis, N. J., Brunt, D., & Wu, C. F. (2024) · ACS Omega · doi:10.1021/acsomega.4c05469 · Cited by 8 · see citing works

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro

Jónsdóttir, H. R., Siegrist, D., Julien, T., Padey, B., Bouveret, M., Terrier, O., Pizzorno, A., Huang, S., Samby, K., Wells, T. N. C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113058 · Cited by 29 · see citing works